Celldex plans up to $60 million at-the-market offering of common stock

Cantor Fitzgerald to assist; proceeds earmarked for working capital

By Marisa Wong

Morgantown, W.Va., May 19 – Celldex Therapeutics, Inc. has arranged an up to $60 million at-the-market offering of common stock, according to a 424B5 filing with the Securities and Exchange Commission.

Cantor Fitzgerald & Co. will be the underwriter.

Proceeds will be used for working capital and other general corporate purposes.

The last reported sale price of the company’s stock (Nasdaq: CLDX) on May 18 was $3.93 per share.

Celldex is a Hampton, N.J.-based biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.